Effects of the re-esterified triglyceride (rTG) form of omega-3 supplements on dry eye following cataract surgery

Jongyeop Park,Young-Sik Yoo,Eunhae Shin,Gyule Han,Kyungyoon Shin,Dong Hui Lim,Tae-Young Chung

DOI: https://doi.org/10.1136/bjophthalmol-2020-317164

2020-09-11

British Journal of Ophthalmology

Abstract:Background/Aims To evaluate the clinical outcomes of the systemic re-esterified triglyceride (rTG) form of omega-3 fatty acids in patients with dry eye symptoms after cataract surgery. Methods This prospective comparative cohort study comprised 66 patients complaining of new-onset non-specific typical dry eye 1 month after uncomplicated cataract surgery. Subjects were randomly allocated into control and omega-3 groups based on administration of the systemic rTG form of omega-3 fatty acids for 2 months, in addition to use of artificial teardrop. Ocular surface parameters (Schirmer’s test, tear break-up time, corneal staining score and matrix metalloproteinase-9 (MMP-9)) and subjective questionnaire results (Ocular Surface Disease Index (OSDI)) and Dry Eye Questionnaire [DEQ]) for dry eye were evaluated before and after omega-3 supplementation. Results Two months after omega-3 supplementation, the Oxford score was lower in the omega-3 group than in the control group. There was an improvement of subjective symptom scores of OSDI and DEQ in the omega-3 group (both p<0.05). The ratio of increasing MMP-9 level in the omega-3 group was lower than that in the control group (p=0.027). Conclusion The rTG form of omega-3 supplementation might be related to reduction of ocular surface inflammation rather than secretion of tears, and it might be effective for non-specific typical dry eye after uncomplicated cataract surgery. Trial registration Number NCT04411615.

ophthalmology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to evaluate the clinical effect of systemic supplementation of omega - 3 fatty acids in the form of re - esterified triglyceride (rTG) on dry eye symptoms in patients with non - specific typical dry eye disease that occurs after cataract surgery. Specifically, the study aims to explore whether this specific form of omega - 3 supplement can improve the subjective symptoms and objective ocular surface parameters of patients with postoperative dry eye disease.

### Research Background and Objectives

Dry eye disease (DED) is an inflammatory disease caused by multiple factors, which may lead to decreased vision, ocular surface damage, discomfort, and an overall decline in quality of life. Current treatment strategies include enhancing tear volume and quality, reducing ocular inflammation, treating underlying eyelid diseases, and adjusting diet and lifestyle. Omega - 3 fatty acids (such as EPA and DHA) are considered potential dietary supplements for the treatment of dry eye disease because they can regulate the arachidonic acid pathway and reduce the inflammatory response.

Although previous studies have shown that omega - 3 is beneficial for dry eye disease, the results of different randomized controlled trials are inconsistent. Therefore, this study specifically focuses on the effect of omega - 3 fatty acids in the form of rTG on dry eye disease after cataract surgery, in order to provide more definite evidence for the clinic.

### Methods

This is a prospective comparative cohort study. A total of 66 patients with new - onset non - specific typical dry eye symptoms 1 month after cataract surgery were included. Participants were randomly assigned to the control group and the omega - 3 group. Both groups of patients used artificial tears, while the omega - 3 group additionally received omega - 3 fatty acid supplementation in the form of rTG for a period of 2 months.

The study evaluated the following indicators:
- Objective parameters: Schirmer test, tear break - up time (TBUT), corneal staining score (Oxford score), and matrix metalloproteinase - 9 (MMP - 9) level.
- Subjective questionnaires: Ocular Surface Disease Index (OSDI) and Dry Eye Questionnaire (DEQ).

### Results

After 2 months of omega - 3 supplementation, the Oxford score in the omega - 3 group was significantly lower than that in the control group (p < 0.05). The subjective symptom scores of OSDI and DEQ in the omega - 3 group also improved (p < 0.05). In addition, the proportion of increased MMP - 9 levels in the omega - 3 group was lower than that in the control group (p = 0.027).

### Conclusions

Omega - 3 fatty acid supplementation in the form of rTG may improve non - specific typical dry eye symptoms after cataract surgery by reducing ocular surface inflammation rather than increasing tear secretion. Therefore, oral omega - 3 fatty acids in the form of rTG can be an effective adjuvant means for managing dry eye disease after cataract surgery.

### Formula Representation

The statistical analysis formulas involved in the article are as follows:

- Mean ± standard deviation: $\text{mean} \pm \text{SD}$
- Wilcoxon signed - rank test: used to analyze intra - group changes
- $\chi^2$ test: used to evaluate the treatment differences of MMP - 9 positive enzyme biomarker categorical variables

These results indicate that omega - 3 fatty acid supplementation in the form of rTG has a significant effect on alleviating the symptoms of dry eye disease after cataract surgery, especially showing an advantage in reducing ocular surface inflammation.